SCYX Latest Press Releases

-- January 21, 2026 --

SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 Globe Newswire 8:00 AM

-- November 19, 2025 --

SCYNEXIS Completes Transfer of BREXAFEMME New Drug Application to GSK Globe Newswire 7:00 AM

-- November 17, 2025 --

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections Globe Newswire 10:15 AM

-- November 5, 2025 --

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update Globe Newswire 4:20 PM

-- October 15, 2025 --

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study Globe Newswire 8:00 AM

-- September 30, 2025 --

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) Globe Newswire 8:00 AM

-- September 4, 2025 --

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software